Skip to search formSkip to main contentSkip to account menu

lanoteplase

Known as: 7-L-Glutamine-245-L-Methionine 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

SUN 9216

Broader (1)

alteplase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
THROMBOLYTIC & CYTOTOXIC EFFECT OF DIFFERENT HERBAL EXTRACTS
An in-vitro thrombolytic model was used to check the clot lysis effect of four herbal extracts viz., Honey, Nigella sativa… 
2007
2007
Characterization of the Hepatic Disposition of Lanoteplase, a Rationally Designed Variant of Tissue Plasminogen Activator in Rodents
Lanoteplase is a recombinant mutant of tissue-type plasminogen activator (t-PA) that was developed with an aim to overcome the… 
2003
2003
Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.
BACKGROUND Quantification of fibrinolytic activity (FAct) in clinical practice has been abandoned because of the complexity of… 
Review
2002
Review
2002
Gateways to Clinical Trials. June 2002.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Review
2000
Review
2000
Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction
New bolus fibrinolytic agents derived from the recombinant human tissue plasminogen activator (t-PA) have emerged as a new means… 
2000
2000
Lanoteplase
Abstract▴ Lanoteplase is a recombinant plasminogen activator, which when administered as a single bolus intravenous injection… 
2000
2000
Lanoteplase
Thrombolytic agents, given with the aim of restoring infarct artery patency and myocardial perfusion, have become the cornerstone… 
2000
2000
Lanoteplase
Early reperfusion therapy, either medically or mechanically induced, limits infarct size, preserves left ventricular function and… 
1999
1999
Validation of an ELISA for the quantitation of lanoteplase, a novel plasminogen activator.
An ELISA was developed and validated for the quantitation of lanoteplase in human citrated plasma. The ELISA employed a… 
1998
1998
Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction.
The fibrinolytic capacity of patients with acute myocardial infarction (AMI) is known to be impaired. The primary regulatory… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)